All Phenotypes Cdkn2a<tm2.1Rdp> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Cdkn2a^tm2.1Rdp
targeted mutation 2.1, Ronald DePinho
MGI:2384177

Summary

14 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp	involves: 129S6/SvEvTac * FVB/N	MGI:3814389
ht2	Cdkn2a^tm2.1Rdp/Cdkn2a⁺	involves: 129S6/SvEvTac * FVB/N	MGI:3814390
cn3	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Pdx1-cre)89.1Dam/0	involves: 129 * C57BL/6 * CBA * FVB/N	MGI:5308962
cn4	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pdx1-cre)89.1Dam/0	involves: 129 * C57BL/6 * CBA * FVB/N	MGI:5308954
cn5	Cdkn2a^tm2.1Rdp/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Pdx1-cre)89.1Dam/0	involves: 129 * C57BL/6 * CBA * FVB/N	MGI:5308961
cn6	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Tg(Pdx1-cre)89.1Dam/0	involves: 129 * C57BL/6 * CBA * FVB/N	MGI:5308963
cn7	Cdkn2a^tm2.1Rdp/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pdx1-cre)89.1Dam/0	involves: 129 * C57BL/6 * CBA * FVB/N	MGI:5308951
cn8	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:5659885
cn9	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:5659896
cn10	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Tg(Pdx1-cre)6Tuv/0	involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N	MGI:5502381
cx11	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Nf1^tm1Tyj/Nf1⁺	involves: 129S2/SvPas * 129S6/SvEvTac	MGI:3776068
cx12	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Tg(GFAP-TVA)5Hev/0	involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N	MGI:3835352
cx13	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Tg(NES-TVA)J12Ech/0	involves: 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:3835366
cx14	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp X/Tg(Tyr-HRAS)60Lc	involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB	MGI:2676124

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp
Genetic Background	involves: 129S6/SvEvTac * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased tumor incidence ( J:71394 , J:88365 )

• between 28 and 58 weeks, 10 out of 39 mice develop tumors unlike wild-type mice (J:71394)

• increase in spontaneous and carcinogen-induced tumor incidence, but less than in Cdkn2a^tm1Rdp mice (J:88365)

• 12% and 5% of spontaneous and DMBA-induced tumors, respectively, that form in mutants are melanomas (J:88365)

increased incidence of tumors by chemical induction ( J:71394 , J:88365 )

• following treatment with DMBA, 50% of mice develop tumors by week 23 compared to later than week 35 for similarly treated wild-type mice (J:71394)

• following treatment with DMBA, mice develop lung adenomas that are more aggressive than in similarly treated wild-type mice (J:71394)

• following treatment with DMBA, mice exhibit an increase in spindle-cell neoplasms compared to in similarly treated wild-type mice (J:71394)

• treatment of mice with urethane results in a 4-fold increase in the number of lung adenomas compared to in similarly treated wild-type mice (J:71394)

increased lymphoma incidence ( J:88365 )

• 18% of spontaneous tumors that form in mutants are histiocytic lymphomas

increased small lymphocytic lymphoma incidence ( J:88365 )

• spontaneous lymphocytic lymphomas are not observed in mutants, however 40% of DMBA-induced tumors are small lymphocytic lymphomas

increased sarcoma incidence ( J:88365 )

• 29% of spontaneous tumors that form in mutants are malignant spindle cell neoplasms, most likely soft tissue sarcomas

• 23% of spontaneous tumors that form are angiosarcomas

• 30% of DMBA-induced tumors are malignant spindle cell neoplasms

increased osteosarcoma incidence ( J:88365 )

• 18% of spontaneous tumors that form in mutants are osteosarcomas

immune system

increased splenocyte proliferation ( J:71394 )

• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40

increased thymus weight ( J:71394 )

thymus hyperplasia ( J:71394 )

• the thymus exhibits increased cortical thickness and cellularity

increased double-positive T cell number ( J:71394 )

• mice exhibit a marked increased in the double positive compartment

increased CD4-positive, alpha-beta T cell number ( J:71394 )

increased CD8-positive, alpha-beta T cell number ( J:71394 )

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:71394 , J:88365 )

• following treatment with DMBA, 50% of mice develop tumors by week 23 compared to later than week 35 for similarly treated wild-type mice (J:71394)

• following treatment with DMBA, mice develop lung adenomas that are more aggressive than in similarly treated wild-type mice (J:71394)

• following treatment with DMBA, mice exhibit an increase in spindle-cell neoplasms compared to in similarly treated wild-type mice (J:71394)

• treatment of mice with urethane results in a 4-fold increase in the number of lung adenomas compared to in similarly treated wild-type mice (J:71394)

hematopoietic system

increased splenocyte proliferation ( J:71394 )

• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40

increased thymus weight ( J:71394 )

thymus hyperplasia ( J:71394 )

• the thymus exhibits increased cortical thickness and cellularity

increased double-positive T cell number ( J:71394 )

• mice exhibit a marked increased in the double positive compartment

increased CD4-positive, alpha-beta T cell number ( J:71394 )

increased CD8-positive, alpha-beta T cell number ( J:71394 )

cellular

increased splenocyte proliferation ( J:71394 )

• unsorted splenocytes exhibit increased proliferation compared to wild-type cells when stimulated with CD3 and CD28 but not LPS or IgM with CD40

endocrine/exocrine glands

increased thymus weight ( J:71394 )

thymus hyperplasia ( J:71394 )

• the thymus exhibits increased cortical thickness and cellularity

skeleton

increased osteosarcoma incidence ( J:88365 )

• 18% of spontaneous tumors that form in mutants are osteosarcomas

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a⁺
Genetic Background	involves: 129S6/SvEvTac * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased tumor incidence ( J:71394 )

• between 28 and 58 weeks, 4 out of 60 mice develop tumors unlike wild-type mice

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Pdx1-cre)89.1Dam/0
Genetic Background	involves: 129 * C57BL/6 * CBA * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Kras^tm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(Pdx1-cre)89.1Dam mutation (2 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 13.1 weeks

• 25% of tumors exhibit sarcomatoid carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 75% of tumors exhibit well differentiated ductal adenocarcinoma histology

increased metastatic potential ( J:108298 )

• 25% of tumors exhibit metastasis

endocrine/exocrine glands

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 13.1 weeks

• 25% of tumors exhibit sarcomatoid carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 75% of tumors exhibit well differentiated ductal adenocarcinoma histology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic ductal adenocarcinoma		DOID:3498		J:108298

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pdx1-cre)89.1Dam/0
Genetic Background	involves: 129 * C57BL/6 * CBA * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 7.2 weeks

• 60% of tumors exhibit anaplastic carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 40% of tumors exhibit well differentiated ductal adenocarcinoma histology

increased metastatic potential ( J:108298 )

• 20% of tumors exhibit metastasis

endocrine/exocrine glands

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 7.2 weeks

• 60% of tumors exhibit anaplastic carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 40% of tumors exhibit well differentiated ductal adenocarcinoma histology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic ductal adenocarcinoma		DOID:3498		J:108298

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Pdx1-cre)89.1Dam/0
Genetic Background	involves: 129 * C57BL/6 * CBA * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:108298 )

• 19% of tumors exhibit sarcomatoid differentiation

• mutants develop pancreatic tumors with an average latency of 14.7 weeks

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 81% of tumors exhibit well differentiated ductal adenocarcinoma histology

increased metastatic potential ( J:108298 )

• 25% of tumors exhibit metastasis

endocrine/exocrine glands

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 14.7 weeks

• 19% of tumors exhibit sarcomatoid differentiation

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 81% of tumors exhibit well differentiated ductal adenocarcinoma histology

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Tg(Pdx1-cre)89.1Dam/0
Genetic Background	involves: 129 * C57BL/6 * CBA * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 18.3 weeks

• 100% of tumors are sarcomatoid in histology

increased metastatic potential ( J:108298 )

• 33% of tumors exhibit metastasis

endocrine/exocrine glands

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 18.3 weeks

• 100% of tumors are sarcomatoid in histology

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Pdx1-cre)89.1Dam/0
Genetic Background	involves: 129 * C57BL/6 * CBA * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 6.5 weeks

• 20% of tumors exhibit anaplastic carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 80% of tumors exhibit well differentiated ductal adenocarcinoma histology

endocrine/exocrine glands

increased pancreas tumor incidence ( J:108298 )

• mutants develop pancreatic tumors with an average latency of 6.5 weeks

• 20% of tumors exhibit anaplastic carcinoma histology

increased pancreatic ductal adenocarcinoma incidence ( J:108298 )

• 80% of tumors exhibit well differentiated ductal adenocarcinoma histology

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic ductal adenocarcinoma		DOID:3498		J:108298

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Trp53^tm1Brn/Trp53^tm1Brn
Genetic Background	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:124682 )

• mice inoculated with an adenovirus expressing cre recombinase (ad-cre) by inhalation have a median survival of 29 weeks after ad-cre inoculation

cardiovascular system

lung hemorrhage ( J:124682 )

• mice inoculated with ad-cre exhibit a high frequency of fatal pulmonary hemorrhage

respiratory system

lung hemorrhage ( J:124682 )

• mice inoculated with ad-cre exhibit a high frequency of fatal pulmonary hemorrhage

increased lung tumor incidence ( J:124682 )

• some ad-cre inoculated mice develop lung tumors with low tumor multiplicity

neoplasm

increased lung tumor incidence ( J:124682 )

• some ad-cre inoculated mice develop lung tumors with low tumor multiplicity

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺
Genetic Background	involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:124682 )

• mice inoculated with an adenovirus expressing cre recombinase (ad-cre) by inhalation have a median survival of 24 weeks after ad-cre inoculation

neoplasm

increased metastatic potential ( J:124682 )

• 3 of 15 (20%) ad-cre inoculated mice exhibit metastasis

increased lung adenocarcinoma incidence ( J:124682 )

• mice inoculated with ad-cre by inhalation develop infrequent highly lethal tumors; all tumors are adenocarcinomas

respiratory system

increased lung adenocarcinoma incidence ( J:124682 )

• mice inoculated with ad-cre by inhalation develop infrequent highly lethal tumors; all tumors are adenocarcinomas

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Kras^tm4Tyj/Kras⁺ Tg(Pdx1-cre)6Tuv/0
Genetic Background	involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:198619 )

• median survival 15.5 weeks

neoplasm

increased pancreas tumor incidence ( J:198619 )

• starting between 6 and 24 weeks with metastasis

increased pancreas adenoma incidence ( J:198619 )

• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas

increased pancreatic intraepithelial neoplasia incidence ( J:198619 )

increased adenocarcinoma incidence ( J:198619 )

• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas

growth/size/body

weight loss ( J:198619 )

• starting between 6 and 24 weeks

distended abdomen ( J:198619 )

• increased girth starting between 6 and 24 weeks

liver/biliary system

jaundice ( J:198619 )

• starting between 6 and 24 weeks

homeostasis/metabolism

ascites ( J:198619 )

• starting between 6 and 24 weeks

endocrine/exocrine glands

increased pancreas tumor incidence ( J:198619 )

• starting between 6 and 24 weeks with metastasis

increased pancreas adenoma incidence ( J:198619 )

• adenocarcinomas in 21 of 22 invasive carcinomas in the pancreas

increased pancreatic intraepithelial neoplasia incidence ( J:198619 )

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Nf1^tm1Tyj/Nf1⁺
Genetic Background	involves: 129S2/SvPas * 129S6/SvEvTac

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Nf1^tm1Tyj mutation (3 available); any Nf1 mutation (157 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:131914 )

N	• unlike other mice with at least one Nf1^tm1Tyj allele, mice do not display malignant peripheral nerve sheath tumors or neurofibromas

increased lymphoma incidence ( J:131914 )

• hematopoietic neoplasms, especially lymphoma, are seen in some mice

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Tg(GFAP-TVA)5Hev/0
Genetic Background	involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Tg(GFAP-TVA)5Hev mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:125535 )

• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 25% compared to 85% survival in similarly treated Tg(GFAP-TVA)5Hev mice

neoplasm

increased glioma incidence ( J:125535 )

• 23 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 18 grade II (similar to human oligodendroglioma) and 5 grade III (similar to anaplastic oligodendroglioma)

nervous system

increased glioma incidence ( J:125535 )

• 23 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 18 grade II (similar to human oligodendroglioma) and 5 grade III (similar to anaplastic oligodendroglioma)

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp Tg(NES-TVA)J12Ech/0
Genetic Background	involves: 129S6/SvEvTac * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Tg(NES-TVA)J12Ech mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:125535 )

• after 84 days, mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB exhibit 20% compared to 50% survival in similarly treated Tg(NES-TVA)12Hev mice

neoplasm

increased glioma incidence ( J:125535 )

• 22 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 21 grade II (similar to human oligodendroglioma) and 1 grade III (similar to anaplastic oligodendroglioma)

nervous system

increased glioma incidence ( J:125535 )

• 22 gliomas are discovered in 28 mice transfected with replication-competent ALV splice acceptor viral vector expressing PDGFB

increased oligodendroglioma incidence ( J:125535 )

• 21 grade II (similar to human oligodendroglioma) and 1 grade III (similar to anaplastic oligodendroglioma)

Allelic Composition	Cdkn2a^tm2.1Rdp/Cdkn2a^tm2.1Rdp X/Tg(Tyr-HRAS)60Lc
Genetic Background	involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Rdp mutation (2 available); any Cdkn2a mutation (62 available)
Tg(Tyr-HRAS)60Lc mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased melanoma incidence ( J:85075 )

• 75 week melanoma free survival as opposed to 89 weeks for wild-type mice

• functioning of p19^ARF was compromised in more than half of the tumors examined

• about 40% of tumors overexpressed p53 as demonstrated by Western blot analysis

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/30/2024 MGI 6.23